Causaly

📢 Live Today! Join Novartis, Gartner, and Causaly for an exclusive live session on how AI is revolutionizing life sciences R&D. 🔍 - Gartner’s emerging AI technologies to watch in 2025 🧬 - How Novartis applies AI in real-world R&D processes 🖥️ - Causaly’s AI platform in action 📅 Today - Thursday, August 14 ⏰ 3:30PM EDT / 8:30PM BST Still time to register ➡️ https://hubs.la/Q03CKFK20 Can't make the live session? We'll share the recording with all registrants afterwards! #LifeSciences #AI #DrugDiscovery #Biotech

Sampling bias. Familiarity bias. Positivity bias. These shape R&D outcomes more than we realize. In fact, Applied Clinical Trials highlights that bias contributes to 90% of R&D decision-making failures. In this latest article, our Director of Scientific Affairs, Stavroula Ntoufa explores how domain-specific AI can help detect bias earlier, accelerate evidence discovery, and strengthen the integrity of research. Read here: https://hubs.la/Q03F-K770

The best way to explain what we do is to let our customers speak for themselves. Behind every feedback like this is a team of R&D leaders who are accelerating discovery, asking bigger questions, and uncovering answers. Curious how Causaly could help your team do the same? Reach out: https://hubs.la/Q03DwmzF0

AI is rewriting the rules of life sciences R&D. On August 14, Novartis, Gartner and Causaly will reveal how AI and other breakthrough technologies are transforming research. You'll learn: 🔍 Gartner’s top life sciences technologies to watch in 2025 🧪 How Novartis applies AI to real discovery workflows ⚙️ How Causaly powers faster, evidence-based research, at scale Don’t miss this chance to learn from leaders shaping the future of research, in collaboration with our peers at Pharmaceutical Executive. Register here: https://hubs.la/Q03CjTWy0 #R&D #AI #LifeSciences

When the DIA (Drug Information Association) wanted to explore how AI is reshaping early drug discovery, they tapped into the expertise of our Director of Scientific Affairs, Stavroula Ntoufa. Her article highlights how AI is accelerating target identification, streamlining research workflows, and enabling faster, smarter evidence-based decisions that move science forward. DIA brings together leading minds from industry, regulators, and academia. Having Causaly’s voice featured here is proof that our team isn’t just part of the conversation, we’re helping lead it. Read the full article: https://hubs.la/Q03Cjp-v0

Making an impact is what drives us. Every day, we partner with teams across life sciences to help them move faster, uncover insights sooner, and make confident, evidence-based decisions. It’s incredibly rewarding to hear how that work is being felt by end users. This kind of feedback reminds us why we’re here: to empower researchers, scientists, and decision-makers with the tools they need to shape the future of healthcare. If you're curious about how Causaly can accelerate discovery in your organization, we’d love to show you what’s possible https://hubs.la/Q03BJG9V0

Join us on Thursday, August 14th, for an exclusive discussion featuring Jeremy Jenkins, US Head of Discovery Sciences, Novartis, Reuben Harwood, PhD, Director Analyst of Life Sciences R&D, Gartner, host from Pharmaceutical Executive and scientific expert Janis Tam, PhD from Causaly, as we explore how AI is transforming discovery, decision-making, and research operations across the life sciences industry. As data volumes grow and research complexity increases, traditional approaches can’t keep up. In this exclusive session, you'll gain insights into Gartner, learn how Novartis is applying AI to accelerate early discovery, and see how Causaly enables faster, evidence-based decisions across R&D workflows. Register now: https://hubs.la/Q03Bvr3B0

The adoption of AI tools is gradually becoming the backbone of innovation in life sciences R&D. Join experts like Jeremy Jenkins Head of Discovery Sciences at Novartis, Reuben Harwood, PhD Director Analyst at Gartner and Causaly for an exclusive conversation on how AI is accelerating discovery, enhancing decision-making, and transforming research operations. If you're a scientific leader, researcher, or strategist, this session will equip you with actionable strategies to harness AI for measurable impact in your R&D operations. You’ll gain: • Understand the emerging technologies shaping life sciences R&D • Learn how Novartis is applying AI in real-world target ID and early discovery • See how Causaly enables evidence-based decisions across R&D workflows. Register here to secure your spot https://hubs.la/Q03z_zPg0

We recently heard this from one of our customers, and it's why Causaly exists. To help R&D teams cut through complexity, find insights faster, and make smarter, evidence-based decisions. If you're trying to: ✅ Accelerate drug discovery & development ✅ Streamline literature reviews ✅ And make your team more efficient Causaly is the strategic partner you need. Curious what Causaly could do for you? Find out here https://hubs.la/Q03zvpwb0

We recently heard this from one of our customers, and it's why Causaly exists. To help R&D teams cut through complexity, find insights faster, and make smarter, evidence-based decisions. If you're trying to: ✅ Accelerate drug discovery & development ✅ Streamline literature reviews ✅ And make your team more efficient Causaly is the strategic partner you need. Curious what Causaly could do for you? Find out here https://hubs.la/Q03zvpwb0